Fed Report Calls on NIH to Blaze Personalized Medicine Trail


Loading...

Personalized Medicine Watch by John Russell

October 14, 2008 | It’s a busy time on the personalized medicine front. The recently-released federal government report, Priorities for Personalized Medicine, is gradually attracting attention. The state of Wisconsin last week jumped into the race to become a center for personalized medicine. And a group of technology providers has joined Scripps Translational Science Institute (STSI) to study to what extent people make behavioral changes when they are provided with genetic screening and information about their various risk factors.

Back in 2001, the President’s Council of Advisors on Science and Technology were instructed to develop   suggested policy around personalized medicine’s needs. The result, Priorities for Personalized Medicine, is not all that profound—“HHS, should join with the private sector to create a public/private sector ‘Personalized Medicine R&D Roadmap’ for coordinating discovery and translational research in personalized medicine”—but it’s a start.

NIH is urged to take in lead in directing “critical investments in the enabling tools and resources essential to moving beyond genomic discoveries to personalized medicine products and services of patient and public benefit.” Specifically, the report calls on NIH to spur efforts to develop an integrated nationwide network of standardized biospecimen repositories and to fund academic/industry projects addressing biomarker standardization, statistical methods.

Meanwhile Wisconsin governor Jim Doyle today announced the Wisconsin Genomics Initiative, a collaborative research effort among the Marshfield Clinic, Medical College of Wisconsin (MCW), University of Wisconsin School of Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). Wisconsin has long been a leader in genomic research. The Marshfield Clinic has undertaken the largest population-based genetic research project in the country which approximately 20,000 people have contributed their DNA and given researchers access to their complete electronic health records.

The other big news last week was the announcement that MicrosoftNavigenics, and Affymetrix would join forces with the Scripps Translational Science Institute (STSI) to launch a novel research study to assess the behavioral impact of personal genetic testing. The goal of the study is to discover if participating in personal genomic testing improves people’s health by encouraging them to make positive lifestyle decisions and medical monitoring.

The study will offer genetic scans by Navigenics to up to 10,000 employees, friends, and family of the nonprofit Scripps Health system in San Diego and monitor participants’ changes in behavior for two decades. Participants will report their lifestyle changes at 3- and 12-month intervals after they receive their Navigenics results. They will also take part in periodic health surveys over the next two decades. A complete database of genomic and clinical information will be maintained at the Scripps Genomic Medicine program. For more read the Bio-IT World article on the program.

Related Links
Priorities for Personalized Medicine report:
http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf.

The Wisconsin initiative:
http://www.eurekalert.org/pub_releases/2008-10/mc-gda101008.php
http://www.forbes.com/feeds/ap/2008/10/10/ap5537035.html

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

oracle20723
The Role of Analytics in Transforming Healthcare
Sponsored by Oracle

Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders.

Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.



pegasystems
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency
Sponsored by Pegasystems

Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are:

  • Potentially stunning return on investment at multiple levels.
  • A 500%, or better, increase in application development time by directly executing business requirements
  • Improved customer retention
  • A 50% possible reduction in training time

Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.



Cmed paper
Next-gen Cloud-based eClinical
Sponsored by Cmed Technology

New technologies are available to leverage Cloud Computing in  managing clinical trial data. This paper discusses a next generation eClinical
platform that:

  • Speeds trial set up
  • Accommodates changes with zero downtime
  • Integrates effectively with other clinical trial technology systems

It is offered with either software-as-a-service (SaaS), or turnkey infrastructure options in which the user organization operates their own cloud using their IT teams, within their data centers. Read this paper to learn and decide how best to leverage cloud computing’s many strengths for your organization’s  particular needs.



Life Science Webcasts & Podcasts

Medidata Solutions

Evaluating a Risk-based Approach to Good Clinical Practice 

medidata5_podcastThe verification of source documents by study monitors at investigational sites is considered a good clinical practice by regulatory authorities overseeing clinical research, and is extremely important to ensuring data quality in clinical trials. Today’s challenging environment is prompting study teams to explore the use of risk-based approaches to monitoring that do not compromise data quality, but allow limited resources to be directed more effectively to where they’re most needed and to the most critical review activities.

In this podcast, industry experts and executives from Medidata will address questions such as:

  • Why are regulatory agencies and industry open to evaluating the new approaches in site monitoring and source document verification (SDV), and what attitudes and reactions towards less than 100% SDV?
  • What factors do research sponsors need to consider in adopting risk-based site monitoring?


Download Now 



More Podcasts

Job Openings

mskc logo
Software Engineer – Computational Biology Center

Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.

Apply: www.mskcciscareers.org.  Equal opportunity and affirmative action employer.

Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.